Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Lilly Math: Subtracting Employees And Animal Health Equals Pharma Growth

Oct 25 2017

• By Mandy Jackson

GoldKeyInPuzzle_1200x675

Related Content

Insulin Market Competition: Payers Watching FDA 'Transition' Policy

Jul 07 2017

Can Lilly's Abemaciclib Overcome Third Place Finish In CDK4/6 Race?

Mar 21 2017

Novartis in $28.5bn+ mega-deal with GSK, Lilly

Apr 22 2014

FDA OK's Lilly's Taltz; Rival To Novartis' Cosentyx

Mar 23 2016

Zoetis raises $2.2bn in IPO but other pharma majors to retain animal health

Feb 04 2013

Revamped Novartis In Good Shape At 3Q Ahead Of CEO Succession

Oct 24 2017

And Then There Were Three: Lilly's Verzenio Approved For Breast Cancer

Sep 29 2017

Lilly's Abemaciclib On Par With Ibrance In Breast Cancer, But Not 'Clearly Superior'

Sep 11 2017

Finance Watch: Lilly Cuts 3,500 Jobs Globally To Drive Growth

Sep 08 2017

Novo's Semaglutide Outperforms Lilly's Trulicity In SUSTAIN 7

Aug 16 2017

Lilly/Incyte's JAK Inhibitor Baricitinib Poised For FDA Approval After All

Aug 30 2017

Related Companies

Eli Lilly and Company

Pfizer Inc.

Boehringer Ingelheim GmbH

Novartis AG

GSK plc

Novo Nordisk A/S

Sanofi

Incyte Corporation

Additional Topics

Sales & Earnings Business Strategies Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window